Related Experiment Video
Updated: Jul 4, 2025
08:06
Absolute Quantification of Cell-Free Protein Synthesis Metabolism by Reversed-Phase Liquid Chromatography-Mass Spectrometry
Published on: October 25, 2019
9.2K
Total serum pentosidine quantification using liquid chromatography-tandem mass spectrometry
Lindsie A Blencowe1,2, Andrea Božović3,4, Evelyn Wong5
1Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Bone Reports
|February 6, 2024
Summary
Pentosidine (PEN), an aging biomarker in bone, can now be measured in serum. A new liquid chromatography tandem mass spectrometry (LC-MS/MS) method accurately quantifies PEN, aiding osteoporosis research.
Area of Science:
- Biochemistry
- Gerontology
- Biomarker Discovery
Background:
- Pentosidine (PEN) is an Advanced Glycation End-product (AGE) accumulating in bone collagen.
- This accumulation is linked to aging and increased fracture risk.
- Bone PEN correlates with serum PEN, suggesting its potential as an osteoporosis biomarker.
Purpose of the Study:
- To develop and validate a method for quantifying total serum Pentosidine (PEN).
- To establish serum PEN as a viable biomarker for osteoporosis and aging.
Main Methods:
- Systematic narrative review of existing PEN quantification methodologies.
- Development of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for total serum PEN.
- Validation of the LC-MS/MS method for sensitivity, precision, and recovery.
Main Results:
- The developed LC-MS/MS method demonstrated high sensitivity (LOD 2 nM, LOQ 5 nM) and precision (%CV < 6.5%).
- Method recovery ranged from 91.2% to 100.7%.
- The LC-MS/MS method is comparable or superior to existing techniques and avoids fluorescence detection limitations.
Conclusions:
- A robust LC-MS/MS method for quantifying serum PEN has been successfully developed.
- This method offers a sensitive and precise tool for measuring a key aging biomarker.
- The technique can be adapted for quantifying other Advanced Glycation End-products (AGEs).
